Eledon Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; filed May 12, 2022. Eledon is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Its lead candidate is tegoprubart, an anti-CD40L antibody being developed for transplant rejection, autoimmune disease and ALS.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $6.6 million | $5.7 million |
| General and administrative expense | $3.2 million | $3.4 million |
| Total operating expenses | $9.9 million | $9.0 million |
| Net loss | $9.9 million | $8.5 million |
| Basic and diluted net loss per share | $0.69 | $0.57 |
| Net cash used in operating activities | $8.2 million | $5.2 million |
Gross profit and operating margins are not meaningful because the company had no product revenue. Cash and cash equivalents were $76.7 million at March 31, 2022, down from $84.8 million at year-end 2021. Working capital was $76.4 million; accumulated deficit was $124.8 million. Total liabilities were $5.1 million, primarily operating lease and current operating liabilities. The filing reports no outstanding debt or committed credit facility.
Changes versus the prior-year quarter
- Net loss increased by $1.4 million. R&D expense rose by $1.0 million, principally from higher external clinical-development/CRO costs as tegoprubart advanced; lower clinical-material production costs partly offset the increase.
- Operating cash use increased by $3.0 million. The filing attributes the 2022 use mainly to net loss and a reduction in accounts payable and accrued expenses.
- Q1 2021 included a $0.5 million income-tax benefit related to deferred tax liabilities from the Anelixis acquisition; no such benefit was recorded in Q1 2022.
Outlook, development and risks
- Management stated cash was expected to fund anticipated needs for at least 12 months from issuance of the financial statements. Eledon expects continuing losses and says additional financing will be needed to advance development and fund operations; actual cash needs could exceed estimates.
- As of March 31, all 54 participants had completed the 12-week Phase 2a ALS study. The filing describes assessments and biomarker analyses but provides no trial results.
- The company reported regulatory clearances for Phase 2a IgA nephropathy studies in Australia, New Zealand and Malaysia, and prior clearances for islet-transplant studies in Canada and the U.S. It completed a nonhuman-primate kidney-transplant study in March 2022 and had approvals to conduct a Phase 1b kidney-transplant study in Canada and the U.K.
- The filing identifies clinical safety and efficacy, trial enrollment and timing, manufacturing and third-party dependence, regulatory approval, competition, intellectual-property protection, COVID-19 disruption and access to future capital as material risks. COVID-19 had caused some study delays and data-collection delays, although its effects had not been material to date.
- The company could sell up to $16.4 million under its ATM program as of March 31, subject to SEC “baby shelf” limits; it had sold no shares under the program through that date. Equity financing could dilute stockholders.
- Potential contractual obligations include ALS TDI license milestones and low-single-digit royalties on future product sales. No liability was recorded for Israeli Innovation Authority grants, which are repayable from royalties if products developed with grant support generate sales. No material legal proceedings or contingencies requiring accrual were reported.
Important facts for investors to verify
- Current cash runway and expected quarterly cash use against the company’s clinical-development plans and financing needs.
- Subsequent ALS study data and progress, enrollment, timing and costs across transplant and IgAN trials; the filing gives no ALS efficacy results.
- Potential dilution and share-count implications: 13,756,788 common shares were outstanding as of May 11, 2022; the filing also reports 1,145,631 common-stock warrants and preferred-stock warrants convertible into approximately 2.8 million common shares, subject to blockers and other terms.
- Whether manufacturing capacity, clinical-trial execution, regulatory review or external events alter the stated development plans or cash outlook.